402 related articles for article (PubMed ID: 31176095)
1. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
2. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
3. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
4. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
5. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
Li L; Wang L; You QD; Xu XL
J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
7. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
8. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
9. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
[TBL] [Abstract][Full Text] [Related]
10. Heat shock protein 90 inhibitors as therapeutic agents.
Gomez-Monterrey I; Sala M; Musella S; Campiglia P
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):313-36. PubMed ID: 22338602
[TBL] [Abstract][Full Text] [Related]
11. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Stravopodis DJ; Margaritis LH; Voutsinas GE
Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
[TBL] [Abstract][Full Text] [Related]
12. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
Özgür A; Tutar Y
Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
14. Hsp90: Friends, clients and natural foes.
Verma S; Goyal S; Jamal S; Singh A; Grover A
Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
[TBL] [Abstract][Full Text] [Related]
15. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
Kim T; Keum G; Pae AN
Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
[TBL] [Abstract][Full Text] [Related]
16. Recent update on discovery and development of Hsp90 inhibitors as senolytic agents.
Dutta Gupta S; Pan CH
Int J Biol Macromol; 2020 Oct; 161():1086-1098. PubMed ID: 32561284
[TBL] [Abstract][Full Text] [Related]
17. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a covalent inhibitor of heat shock protein 90 with antitumor activity that blocks the co-chaperone binding via C-terminal modification.
Li L; Chen N; Xia D; Xu S; Dai W; Tong Y; Wang L; Jiang Z; You Q; Xu X
Cell Chem Biol; 2021 Oct; 28(10):1446-1459.e6. PubMed ID: 33932325
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
Xiao Y; Liu Y
Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
[TBL] [Abstract][Full Text] [Related]
20. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.
Ardi VC; Alexander LD; Johnson VA; McAlpine SR
ACS Chem Biol; 2011 Dec; 6(12):1357-66. PubMed ID: 21950602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
